Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub
https://doi.org/10.64483/jmph-109

Multidisciplinary Management of Depression in Patients with Chronic Illness: Integrating Psychological, Nutritional, Nursing, and Digital Health Approaches.

Aiman Ali Ebrahem Shehab [(1)], Abdulrahman Ahmed Mohammed Moafa[(1)], Mohammed Othman Ibrahim Kamili[(2)], Alaaldeen Ahmed Ibrahim Shehab[(3)], Mohammed Ahmed M Moafa[(4)], Ibrahim Mohammed Ali Muallim[(5)], Khalid Mohammed Ali Sahli[(6)], Adel Mohammed Mousa Hamzi[(7)], Nasser Mohsen Nasser Aljafery[(7)], Anwar Ali Hakami[(1)], Akram Abdulkarim Al-Juhani[(1)], Fahad Ali Mohammad Sweidi [(1)]

[(1)] Eradah hospital for mental health, Ministry of Health, Saudi Arabia
[(2)]Health informatics, General Medical Committee, Ministry of Health, Saudi Arabia
[(3)]Psychologist, General Medical Committee, Ministry of Health, Saudi Arabia
[(4)]Food science and technology Mental Health Eradah hospital for mintal health, Ministry of Health, Saudi Arabia
[(5)]Nursing, Damad General Hospital, Ministry of Health, Saudi Arabia
[(6)]Nurse Technician Damad General Hospital, Ministry of Health, Saudi Arabia
[(7)] Psychologist Jazan Specialist Hospital, Ministry of Health, Saudi Arabia

Abstract

Background: Major Depressive Disorder (MDD) is a highly prevalent condition that frequently co-occurs with chronic medical illnesses, creating a synergistic burden that worsens quality of life, impairs treatment adherence, and increases mortality. The relationship is bidirectional, with medical illness increasing depression risk and depression contributing to the onset and progression of somatic disease.

Aim: This article aims to review the multidisciplinary management of depression in medically ill patients, integrating psychological, pharmacological, nursing, social, and digital health approaches to improve detection and treatment outcomes.

Methods: The review synthesizes epidemiological data, pathophysiological mechanisms (including shared genetics, inflammation, and neurobiological pathways), and evidence from clinical trials and meta-analyses. It evaluates diagnostic challenges, screening tools, and a range of management strategies, including pharmacotherapy (with attention to drug-disease interactions), psychotherapy, neuromodulation, and collaborative care models.

Results: Depression is prevalent across chronic conditions like cancer, cardiovascular disease, and diabetes, with rates often exceeding 20%. Effective management requires an integrated, etiology-driven approach. Antidepressants and adapted psychotherapies demonstrate efficacy, but success depends on careful agent selection to avoid adverse interactions. Collaborative care models, which systematize screening and combine a care manager with psychiatric oversight, consistently yield the best functional and symptomatic outcomes.

Conclusion: A multifaceted, patient-centered strategy that coordinates medical and mental healthcare is essential. Success hinges on moving beyond simple screening to embed management within a structured, multidisciplinary framework that addresses the complex biological, psychological, and social interplay between depression and physical illness.

Keywords: Major Depressive Disorder, Chronic Illness, Comorbidity, Integrated Care, Collaborative Care, Antidepressants, Psychotherapy.

1. Introduction

Major depressive disorder (MDD) represents a highly prevalent psychiatric condition, with a point prevalence approximating one in twenty individuals and a lifetime risk near one in six globally [1]. Prevalence estimates vary across regions and countries, yet depression remains widespread and a principal contributor to years lived with disability worldwide [2]. This condition occurs with particular frequency among patients who have concurrent medical illnesses; in many clinical populations the likelihood of depression is several times greater than in the general population. This elevated burden encompasses both the categorical diagnosis of MDD and subthreshold depressive symptomatology that does not meet full diagnostic criteria. In the present Primer, the term MDD denotes the formal diagnostic entity, depressive symptoms' denotes subthreshold presentations, and ''depression'' is used when referring to both categories or to more general statements. The clinical consequences of comorbid depression are substantial. When depression coexists with chronic medical disease, the combined impact on health is often additive and, in some cases, synergistic,

*Corresponding author e-mail: aashehab@moh.gov.sa (Aiman Ali Ebrahem Shehab).
Receive Date: 21 September 2025, Revise Date: 30 September 2025, Accept Date: 10 October 2025

leading to larger decrements in overall health status than those produced by either condition alone [3].

Comorbid depression frequently diminishes patients' quality of life, thereby amplifying the overall disease burden [4]. The magnitude of this effect on quality of life depends on features of the medical illness, the treatments employed, the resources accessible to the patient, and the severity of depressive symptomatology. Depressive symptoms also impair adherence to medical regimens, a phenomenon documented in conditions such as diabetes mellitus [5] and in patients with brain tumors [6], and they correlate with a greater probability of receiving care that departs from guideline recommendations, as observed among women with breast cancer [7]. Beyond effects on adherence and quality of life, comorbid depression has been linked to poorer prognosis and increased mortality across a range of medical conditions [8,9,10]. Conversely, the presence of mental disorders, including MDD, appears to elevate the subsequent risk of developing diverse medical illnesses later in life, with implications for long-term morbidity and mortality [11]. Large-scale population data corroborate these observations; for example, a nationwide Danish study reported excess life-years lost associated with mental disorders in relation to medical causes [12]. Notably, suicide does not appear to be the principal driver of this excess mortality, and its relative contribution to the increased mortality observed among patients with comorbid depression has declined in some analyses [12,13]. Synthesis of epidemiological evidence, including an umbrella review, indicates nominally significant associations between MDD and elevated mortality across the settings and populations assessed [14]. Nonetheless, the question of causality—whether depression directly increases mortality risk—remains contested and subject to ongoing debate [15]. Overall, the empirical literature underscores that depression in the context of physical illness is common, clinically consequential, and linked to adverse outcomes across multiple domains of patient health, while also highlighting important gaps in causal understanding and the need for integrated approaches to detection and management.

Epidemiology

Major depressive disorder affects about five percent of the general population at any given time [16,17] and carries an approximate lifetime risk of fifteen percent [18]. Prevalence varies by sex, age and medical comorbidity. Women show higher rates than men [18,19]. Older adults, particularly those older than seventy five years, demonstrate greater frequency than younger groups [20,21]. People with medical illnesses exhibit higher rates than those without such illnesses [22,23]. Within hospital settings, roughly twelve percent of inpatients meet criteria for comorbid MDD [22]. In outpatient general medical clinics, about twenty seven percent of patients show depression or depressive symptoms [23]. Estimates derive from heterogeneous studies. The cited meta-analyses combined investigations that differed in disease severity, stage and duration, and that applied varied instruments to assess depression, including self-rated and clinician rated measures. Timing of assessment also varied across studies. Some reports used point prevalence. Others reported prevalence within twelve months or beyond one year after onset of the medical condition. Few meta-analyses systematically compared prevalence across these reference periods. For stroke, investigators examined differences by reference time. For most conditions, pooled prevalence reflects a mean across studies with mixed timing. This methodological diversity contributes to wide ranges in reported rates. For example, studies of hospital inpatients produced a mean prevalence near twelve percent, but individual estimates ranged from five percent to thirty four percent [22]. Readers seeking comprehensive discussion of measurement, sampling and timing issues should consult the extended reviews cited elsewhere [16,17]. Despite variation in methods, a consistent finding emerges: MDD occurs commonly in the general population and even more commonly in groups defined by female sex, advanced age and concurrent medical illness. This pattern has implications for screening and for allocation of clinical resources across care settings. It also underscores the need for standardized study designs when estimating comorbid MDD prevalence in specific medical populations. Standardization would reduce heterogeneity and allow clearer comparison of rates across diseases, across stages of illness and across assessment intervals.

The prevalence of major depressive disorder (MDD) among patients with cancer has been quantified across multiple meta-analyses and large cohort studies, revealing a substantial and clinically meaningful burden. Meta-analytic estimates derived from studies that applied structured diagnostic interviews in oncological and haematological settings indicate a point prevalence of comorbid MDD of approximately 16.3% among patients receiving active treatment in these specialties [24]. Comparable rates have been observed in palliative care populations, with a pooled diagnostic-interview prevalence of 16.5% [24]. When investigations combine diagnostic interviews and self-report instruments, pooled estimates differ according to assessment modality; diagnostic interviews yield a pooled prevalence near 14%, whereas self-report measures produce a wider range, commonly between 7% and 24% [25]. Such modality-dependent differences reflect both instrument sensitivity and the tendency for self-report scales to capture a broader spectrum of distress and subthreshold symptomatology. Across studies, certain sociodemographic and clinical correlates of comorbid MDD emerge consistently. Younger age (<60 years), female sex and greater socioeconomic deprivation are

associated with higher rates of MDD in cancer cohorts [25]. Temporal patterns also appear prevalence tends to be higher during active treatment compared with intervals following treatment completion. For example, pooled estimates from studies using diagnostic interviews indicate a prevalence of 14% during treatment, declining to 9% within the first year after treatment and to 8% one year or later; when self-report instruments are used, prevalence during treatment approximates 27%, with values of 21% and 15% at the corresponding post-treatment intervals [25]. These aggregated findings accord with disease-specific longitudinal observations. In prostate cancer cohorts, reported rates were 17.3% prior to treatment, 14.7% during treatment and 18.4% after treatment [26]. In ovarian cancer cohorts, reported prevalences were 25.3% before treatment, 23.0% during treatment and 12.7% after treatment [27]. Collectively, these results suggest that active disease and its management may be associated with elevated depression risk, although the trajectory of risk is heterogeneous and likely influenced by disease type, treatment modality and psychosocial context. Notably, some investigations failed to detect differences in MDD prevalence according to the timing of initial treatment or to whether treatment intent was curative or palliative, and meta-analyses have reported insufficient data to stratify prevalence reliably by cancer stage or specific therapeutic approaches [24,25]. This heterogeneity underscores an important methodological limitation of existing literature: many syntheses pool studies that use different case definitions, assessment instruments and reference time windows, thereby generating summary estimates that mask clinically relevant variation.



Figure-1: Prevalence of Depression comorbid chronic diseases.

Variation in prevalence across tumour types has been reported repeatedly, though the etiological basis for these differences remains unsettled. High prevalence estimates have been observed in ovarian cancer and in patients with primary brain tumours [27,28]. A large cross-sectional German study that sampled major cancer types identified particularly elevated rates of mood disorders among patients with breast tumours, women with reproductive tract malignancies and individuals with renal tumours [29]. Explanations for between-cancer variation likely include multiple interacting factors: tumour site and its functional consequences, sex-specific vulnerability, the burden of comorbid medical conditions, socioeconomic status, the nature and intensity of oncological treatments, the interval since diagnosis and the severity of cancer-related symptoms such as pain and fatigue. Childhood cancer survivors show an elevated risk of MDD in adulthood relative to population comparators, though research on depressive disorders in paediatric oncology populations remains limited and methodologically heterogeneous [30].

Cardiovascular disease cohorts show a broad but consistently elevated prevalence of comorbid MDD that correlates with disease severity. In heart failure, reported prevalences range from approximately 11% in patients with New York Heart Association (NYHA) class I disease to as high as 42% in those with class IV disease, highlighting a strong association between functional impairment and depressive morbidity [8]. Some evidence suggests that younger patients (<60 years) with heart failure may be especially susceptible to depression [31]. Peripheral artery disease cohorts show similarly wide prevalence ranges (3–48%), with greater depression prevalence observed in individuals with more severe symptomatic disease [32]. Following acute myocardial infarction, roughly 28% of patients manifest comorbid MDD [33]. Risk is not uniformly distributed; depression occurs more frequently among women, among patients with anterior infarction, and in individuals with comorbid hypertension, prior myocardial infarction or diabetes mellitus [33,34]. A further meta-analysis corroborated sex differences in post-infarction depression while identifying sex-specific associations with cardiac function: reduced left ventricular ejection fraction correlated with higher depression scores in men but not consistently in women [34].

Metabolic disease populations also demonstrate high prevalence of depressive disorders, with sex differences and age gradients. Estimates indicate comorbid MDD prevalence of approximately 23% among men and 34% among women with type 2 diabetes mellitus [35]. For type 1 diabetes mellitus the pooled MDD prevalence is lower, around 12% [36], yet depressive symptoms are frequently observed in adolescents and young adults with type 1 diabetes (pooled symptom prevalence ~30.04%) [37]. In type 2 diabetes cohorts, younger patients (<65 years) exhibit higher rates of depression (31%) compared with older patients (21%) [35]. Additional metabolic or endocrine conditions demonstrate elevated rates; for example, women with polycystic ovary syndrome exhibit depressive symptom prevalence near 36.6% [38]. These findings underscore the bidirectional interface between metabolic dysregulation and mood disturbances and point to age, sex and disease chronicity as important moderators.

Neurological diseases carry a high burden of depression, often linked to lesion location, disability and disease course. Post-stroke depression based on structured diagnostic interviews shows a pooled

prevalence of 17.7% at a mean follow-up of 6.9 months after stroke, increasing to 33.5% when subthreshold depressive symptoms are included [39]. In the acute post-stroke interval (mean 3.4 weeks), diagnostic-interview prevalence approximates 18.1% [39]. Longitudinal meta-analyses of observational cohorts indicate that nearly one third of patients experience depression at multiple post-stroke time points (<1 month, 6 months, 12 months and beyond) [40]. Depression appears more frequently after left hemisphere stroke and among patients with aphasia [39]. In multiple sclerosis, pooled estimates place MDD prevalence near 21%, with depressive symptom prevalence around 35% [41]. Although women with MS show higher risk of MDD than men, the female-to-male disparity in MS is smaller than that observed in the general population [42]. Evidence regarding the relationship between MS neurological disability and depression is mixed; however, large longitudinal cohorts suggest that baseline comorbid MDD predicts accelerated accumulation of disability over time [43,44]. Epilepsy cohorts report an overall MDD prevalence of 21.9% with higher rates in women (26.4%) than men (16.7%) [45]. Parkinson disease cohorts demonstrate MDD prevalence near 22.9% [46], whereas Alzheimer disease cohorts show lower pooled MDD prevalence estimates around 12.7% [47].

Inflammatory and immune-mediated disorders exhibit elevated rates of depression, with meta-analyses reporting prevalences generally in the 15–25% range across systemic lupus erythematosus, psoriasis, rheumatoid arthritis and inflammatory bowel disease (IBD) [48–51]. Depressive symptom prevalence estimates are often higher: approximately 21.6% in IBD, 28% in psoriasis and 38.8% in rheumatoid arthritis [49,50,51]. Within rheumatoid arthritis, younger age is associated with higher MDD prevalence [50]. IBD subtypes differ; Crohn's disease shows higher MDD prevalence (25.3%) than ulcerative colitis (16.7%), and active disease is associated with substantially higher rates of MDD (40.7%) compared with remission (16.5%) [51]. These patterns highlight the relationship between inflammatory activity, symptom burden and affective disturbance.

When considered together, the epidemiological literature demonstrates that many chronic medical conditions are associated with substantial rates of comorbid MDD, frequently exceeding 10% and often surpassing 20%, implying that depression prevalence in medically ill populations is at least double and commonly severalfold greater than in the general population. Subthreshold depressive symptoms occur even more commonly than syndromal MDD. Age-related patterns vary by disorder; in several conditions younger patients (<65 years) show higher depression prevalence, possibly reflecting the psychological toll of facing severe, chronic illness at a younger life stage [25,31,35]. Associations between comorbid depression and disease severity, activity or progression have been reported for multiple disorders, but causal inference is limited by heterogeneity in study designs, measurement approaches and follow-up intervals. Future research should aim for standardized case definitions, consistent timing of assessments and stratified analyses to identify high-risk subgroups and to clarify temporal and causal relationships between physical disease trajectories and depressive morbidity.

Mechanisms/pathophysiology

The association between chronic medical disorders and major depressive disorder often operates in both directions. Medical illness can increase the risk of depression. Depression can increase the risk of medical illness. Multiple biological and behavioural pathways may explain these links. A single patient may show several of these pathways acting together. This section summarizes key candidate mechanisms and illustrates them with examples from major disease areas. Shared genetic risk offers one plausible mechanism. Large genetic datasets have enabled tests of overlap between genetic liability for MDD and a wide set of somatic outcomes. One analysis correlated an MDD polygenic score with 925 disease outcomes in the UK Biobank. The strongest links occurred with other psychiatric conditions such as anxiety, but associations also appeared with ischaemic heart disease and hypercholesterolaemia and with several inflammatory and haemorrhagic gastrointestinal disorders including oesophagitis and non-infectious gastroenteritis [52]. Re-analyses across multiple genome-wide association study datasets identified some overlap between psychiatric traits and inflammatory disorders. For MDD the most robust overlap after multiple-test correction involved hypothyroidism [53]. Targeted studies produced more specific findings. Multiple large cohorts show genetic overlap between obesity and MDD. Higher polygenic risk for greater body mass index associated with increased risk of atypical depression that features weight gain or increased appetite but did not associate with depression lacking those symptoms [54,55]. The atypical subtype also carried higher polygenic risk for elevated inflammatory markers such as C-reactive protein, suggesting a biological link between adiposity, inflammation and a depressive clinical profile [55]. By contrast, studies that tested genetic overlap between depression and glycaemic traits, type 2 diabetes or coronary disease provided weak or inconsistent support for a shared genetic basis [56–59]. A very large GWAS that included more than one million cases and controls found essentially no overlap between genetic risk for psychiatric disorders and the most common neurological illnesses such as multiple sclerosis, stroke, Parkinson disease, epilepsy and Alzheimer disease [60]. No convincing evidence has emerged to support a genetic overlap between cancer

and depression, beyond small candidate gene reports [61].

Beyond static genetic risk, shared neurobiological and systemic mechanisms may underlie comorbidity. These mechanisms can precede diagnosis of either condition or arise as part of the somatic disease process and thereby increase vulnerability to depressive symptoms. Many of the systems implicated in primary MDD also appear in studies of depression within medical populations. Establishing causality is difficult. Animal models that combine a somatic lesion with valid behavioural readouts for depression are scarce because the induced physical disorder can confound behavioural testing. An exception exists. A mouse study showed that obesity drove anxiety and depression-like behaviour through inflammatory mechanisms independent of weight itself. This experiment links the human genetic findings on obesity, inflammation and atypical depression to a causal biological pathway in an animal model [62]. Human evidence comes largely from observational and cohort studies. Prospective work in cardiovascular cohorts supplies many of the best longitudinal data. Increased activation and impaired feedback regulation of stress systems such as the hypothalamic pituitary adrenal axis and the sympathetic nervous system represent established markers that precede MDD onset in multiple settings [63]. In coronary disease cohorts elevated urinary noradrenaline and higher cortisol levels associated with depressive symptom burden [64,65]. These findings mirror experimental and clinical data that tie stress system dysregulation to mood disturbance.

Inflammation has attracted intensive study as a mediator linking somatic disease and depression. Meta-analyses show that patients with MDD have higher circulating cytokines and CRP and that imaging studies detect signals consistent with neuroinflammation such as elevated translocator protein binding, a proxy for microglial activation [66–69]. Experimental human studies and animal models demonstrate that inflammatory signals can induce transient depressive symptoms. Cytokine administration in humans produces behavioural changes that mimic core depressive features and inflammatory challenges in animals alter affective behaviour [70]. This causal evidence supports the hypothesis that medical disorders with a strong inflammatory component may raise depression risk through immune signaling. Rheumatoid arthritis exemplifies this model. Cytokine pathways have been implicated repeatedly in RA associated with depressive symptoms and specific cytokine targets such as interleukin 6 have been studied in clinical trials [71]. Meta-analyses and pooled patient level re-analyses of randomized controlled trials indicate that cytokine inhibitors, especially agents targeting IL-6 and IL-12/IL-23, reduce depressive symptoms in patients with rheumatoid arthritis, Crohn disease and other inflammatory disorders [72,73]. Some analysts suggest that the antidepressant effect of cytokine blockade is at least partly independent of improvements in pain or physical function. This observation strengthens the case for a direct role of cytokines in mood regulation.

The relationship between immune markers and depression in clinical cohorts is not uniform and varies by study design and by the influence of confounders. In the Heart and Soul cohort depressive symptoms predicted subsequent rises in IL-6 and high-sensitivity CRP over five years, while baseline inflammatory markers did not predict incident depressive symptoms in that sample [74]. Observed associations were strongly modulated by health behaviours including smoking and physical activity. These findings illustrate the bidirectional and behaviorally mediated nature of immune mood links. In metabolic disorders such as type 2 diabetes many cross-sectional studies report correlations between depressive symptoms and inflammatory markers such as CRP [75,76]. In type 1 diabetes the evidence for a consistent inflammatory correlate of depression is sparse [77].

Interactions between stress response systems and immune signaling create integrated paths for comorbidity. HPA axis activation and sympathetic output regulate immune function through bidirectional circuits. These interactions may be especially important in disorders that combine metabolic and inflammatory dysregulation. For example, in diabetes the joint action of stress hormones and cytokines may link glycaemic control, vascular risk and mood disturbance. Structural and functional brain changes provide additional mechanistic bridges. Studies have attempted to relate lesion location, neuroinflammation or regional atrophy to post-lesion depressive risk. Meta-analyses that tested simple lesion location models in stroke largely found null results [78,79]. A connectome approach across five datasets revealed that lesions associated with post-stroke depression converge on a distributed network centered on the left dorsolateral prefrontal cortex rather than on a single anatomic site [80]. That network overlaps targets used in noninvasive brain stimulation therapies that show efficacy for post-stroke depression [81]. In multiple sclerosis neuroinflammatory processes and regional neurodegeneration in circuits tied to mood regulation such as the hippocampus and frontotemporal networks correlate with depressive symptoms in case control studies [82,83]. Reviews summarize the growing literature that links network level dysfunction and mood disturbance in neuroinflammatory disorders [84]. Taken together these lines of evidence point to multiple, interacting mechanisms. Genetic liability explains part of the comorbidity in select pairings such as obesity and atypical depression. Inflammation, stress system dysregulation and neural circuit dysfunction provide biologically plausible routes through which medical disease can produce or exacerbate depressive symptoms. Behavioural factors

and treatment related variables further shape risk. Longitudinal multimodal studies that combine genomics, immune profiling, stress biomarkers, neuroimaging and careful behavioural measurement are necessary to disentangle direction, timing and causality. Such studies will help identify mechanistic subgroups and enable targeted interventions that address the specific biological drivers of depression within medical populations.



Figure-2: Etiology and Mechanisms of Depression comorbid diseases.

Treatment-related mechanisms

Pharmacological treatments used for somatic illnesses and for psychiatric conditions can contribute to the observed comorbidity between major depressive disorder (MDD) and medical disease. Large-scale prescription surveys and pharmacovigilance reports have associated many drugs with an increased probability of concurrent depressive symptoms; one comprehensive review of prescription records from 26,192 adults in the United States identified more than 200 medications linked to a higher likelihood of depression [85]. However, most such associations derive from case reports, spontaneous reporting systems or uncontrolled observational series, and rigorous causal evidence is usually absent. Confounding by indication is a pervasive problem. Several agents that appear on lists of drugs associated with depression include antidepressants from different classes and anxiolytics such as benzodiazepines that are themselves prescribed for mood or anxiety disorders. In such instances the presence of drug exposure is most likely a marker for underlying psychiatric morbidity rather than a direct iatrogenic cause. Similarly, longstanding clinical impressions that particular antihypertensive agents, for example β-blockers, provoke depression have not been substantiated consistently in controlled studies [86]. Conversely, some agents used for somatic indications may exert salutary effects on mood. Statins have been proposed to prevent or ameliorate depressive symptoms through pleiotropic mechanisms that include anti-inflammatory effects, promotion of synaptic plasticity and modulation of neurotransmitter and neuroendocrine systems; observational and some interventional data point to potential beneficial associations, although definitive randomized evidence remains limited [87].

For those medications where a causal relationship with depressive symptomatology is biologically plausible, mechanistic pathways generally converge on systems implicated in primary mood disorders. Candidate mechanisms include direct pharmacodynamic effects on central monoaminergic transmission, indirect consequences for neuroendocrine regulation such as hypothalamic–pituitary–adrenal (HPA) axis modulation, and immune activation with consequent central inflammatory signaling. Immunotherapies provide the clearest clinical and experimental model of treatment-related depression. Interferon-α (IFNα) and interleukin-2 (IL-2) therapies, historically used for viral hepatitis and certain malignancies, produce rapid and reproducible neuropsychiatric effects. Up to 80% of patients receiving IFNα develop mood changes, typically dominated by somatic or neurovegetative features such as marked fatigue, sleep disturbance and appetite loss, often manifesting within weeks of treatment initiation [88]. Meta-analytic estimates from observational studies indicate that approximately 25% of IFNα recipients met criteria for a major depressive episode at 24 weeks and about 28% at 48 weeks of therapy [89]. Prior use of antidepressant medication is associated with lower subsequent incidence of IFNα-induced major depression and with reduced depression severity scores, implying both a prophylactic effect and the participation of common neurobiological pathways [90]. Similarly, IL-2 therapy commonly produces profound fatigue in nearly four out of five treated patients, an effect plausibly linked to immune activation and to overlapping mechanisms that produce neurovegetative depressive symptoms [91].

Biological pathways that translate peripheral drug effects into central mood disturbance include cytokine trafficking across the blood–brain barrier via active transport, afferent vagal signaling, and migration of activated immune cells into the central nervous system. Once central inflammatory signals are engaged they interact with neurotransmitter systems, alter neurotrophic support and synaptic plasticity, and promote excitotoxic cascades and oxidative stress that can impair neuronal integrity and network function. One well-characterized biochemical route involves the kynurenine pathway; peripheral or central inflammatory activation shifts tryptophan metabolism away from serotonin synthesis towards kynurenine and its neuroactive metabolites, some of which are neurotoxic and can reduce serotonergic tone, thereby linking immune activation to monoaminergic dysregulation. Experimental infusion of cytokines or endotoxin in healthy volunteers reliably produces

transient depressive and sickness-behaviour features, providing one of the most robust human models that inflammation can precipitate mood disturbance independent of underlying disease [92]. These experimental findings, together with clinical observations from immunotherapy recipients, demonstrate a biologically coherent route by which treatment regimens can directly induce depressive syndromes.

Behavioural pathways form another major axis linking depression and medical comorbidity. Habitual lifestyle factors such as tobacco use, physical inactivity, hazardous alcohol consumption and poor nutritional choices increase the risk for a broad range of chronic diseases and may mediate, at least in part, the effect of depression on subsequent medical outcomes. Smoking prevalence and nicotine dependence are elevated among people with MDD relative to the general population; those with depression experience greater difficulty achieving and sustaining smoking cessation and higher relapse rates after quit attempts [93]. Smoking is itself a well-established risk factor for multiple somatic conditions, including specific malignancies and cardiovascular and cerebrovascular disease [94,95], and contributes to the burden of neurological disorders such as multiple sclerosis [96]. Longitudinal adolescent cohorts indicate bidirectional associations: early smoking predicts later increases in depressive symptoms, and baseline depression predicts subsequent smoking initiation [97]. These reciprocal influences complicate causal inference but indicate that smoking both contributes to and is maintained by affective morbidity. Population-level analyses suggest that smoking accounts for a substantial fraction of excess mortality associated with depressive disorders [99]. Importantly, smokers who are depressed remain less likely to quit even after development of major comorbidities such as chronic respiratory disease, accentuating the public-health implications [98].

Physical inactivity has been linked robustly with incident depression. Prospective cohort studies demonstrate that low baseline physical activity predicts elevated risk for depressive symptoms over long follow-up intervals, in some analyses extending to a decade, and Mendelian randomization analyses support a causal interpretation for the effect of reduced activity on subsequent depression [100]. Conversely, depressive disorders produce marked reductions in activity and increased sedentary behaviour, thereby increasing vulnerability to metabolic and cardiovascular conditions. In coronary disease cohorts behavioural inactivity accounted for a large portion of the observed association between depression and adverse cardiac outcomes in at least one well-characterized longitudinal sample, indicating the mediating role of exercise behaviour in this setting [101]. Alcohol consumption exhibits dose-dependent relationships with mood. Alcohol use disorder confers high comorbidity with MDD, and biological evidence indicates that excessive alcohol intake induces neurophysiological and metabolic changes that increase vulnerability to depressive states [102]. Even heavy but non-dependent consumption correlates with increased severity of depressive symptoms, and alcohol use frequently complicates clinical course and treatment response [101,102]. Dietary patterns may also influence depression risk and comorbid disease trajectories. Observational literature repeatedly finds that adherence to Mediterranean-style diets is inversely associated with incident depression and with cardiovascular disease risk [103–105]. However, the capacity of dietary modification to alter the depression–comorbidity nexus remains unproven. A controlled trial of multinutrient supplementation designed to emulate components of the Mediterranean diet, incorporating omega-3 fatty acids, selenium, folate and vitamin D3, did not reduce the incidence of MDD among individuals with depressive symptoms or in those with overweight or obesity, suggesting that simple supplementation strategies may be insufficient to modify risk [106].

Medication adherence represents an additional behavioural mechanism that links depression to worse somatic outcomes. Depression is consistently associated with poorer adherence to prescribed therapies and to recommended self-care behaviours, a pattern described in the literature for more than two decades. Empirical studies document reduced adherence to adjuvant endocrine therapy in women with breast cancer who are depressed [107], and lower adherence to self-management regimens in patients with heart failure and diabetes mellitus [108,109]. Objective adherence measures corroborate self-report findings; time-stamped pill-box studies and pharmacy refill analyses reveal inverse relationships between depressive symptom severity and medication adherence. For instance, in a cohort of patients with acute coronary syndrome, greater depressive symptom severity was associated with lower adherence to aspirin therapy as measured objectively, although the study lacked statistical power to link adherence variance to subsequent cardiovascular events [110]. Adherence deficits may be intentional or unintentional; depression appears particularly related to deliberate nonadherence, perhaps through pessimism about treatment benefit, hopelessness or lack of motivation, although few studies have dissected these subtypes systematically. Taken together, behavioural mechanisms plausibly mediate a portion of the relationship between depression and chronic somatic illness, yet they do not fully account for observed associations. Two caveats are important. First, randomized manipulation of long-term behaviours such as smoking cessation, increased physical activity or comprehensive dietary change to test their capacity to break the depression–illness link is challenging and ethically complex; evidence that such interventions eliminate excess medical risk attributable to depression remains lacking. Second, a

large body of prospective observational research includes lifestyle behaviours as covariates and still finds independent associations between depression and adverse medical outcomes, indicating that behavioural factors explain only part of the observed comorbidity. Consequently, treatment-related biological mechanisms and behavioural mediators should be viewed as complementary contributors to a multifactorial architecture linking depression and physical disease. Comprehensive prevention and treatment strategies therefore require integrated approaches that consider iatrogenic pharmacological effects, patient behaviours and the underlying biology that may converge to produce coexisting psychiatric and somatic morbidity.

Psychological factors

The cognitive model situates depression within a diathesis–stress framework and remains applicable to depression that arises in the context of medical disease, albeit with necessary modification. Medical conditions introduce a spectrum of specific threats and stressors that exceed ordinary life stressors. When the demands imposed by illness outweigh an individual's coping resources, depressive syndromes may emerge in accordance with stress and coping formulations [111]. Stressors in physical illness are both acute and chronic. Acute stressors include receipt of a diagnosis, waiting for test results, undergoing procedures, and encountering disease exacerbations. Chronic stressors include ongoing disease management, persistent symptoms, functional decline, altered appearance and loss of autonomy. These enduring demands create a sustained burden that may render depressive responses understandable and adaptive in the face of severe threat rather than purely pathological [112,113]. Recovery requires successful emotional regulation after acute events and effective management of the cumulative load imposed by chronic illness. Failure in these adaptive tasks promotes depression through interacting cognitive, behavioural and social processes, some of which are specific to particular illnesses.

Social factors represent a consistent vulnerability for depression across medical conditions. Poor social support and social isolation amplify risk and worsen trajectories of adjustment [114,115]. The availability of practical and emotional assistance shapes patients' ability to adhere to treatment regimens, maintain daily routines and sustain hope. Intrapersonal traits further modulate vulnerability. Perfectionism and pessimism influence attention to somatic signals, interpretive bias and coping choices, thereby altering susceptibility to depression [116,117,118]. For example, longitudinal cancer research links perfectionism to elevated depressive severity through mechanisms including heightened physiological arousal and reliance on maladaptive coping such as rumination, excessive resting when fatigued, avoidance and distraction [119]. These individual predispositions interact with disease-related stress to shape clinical outcomes. Illness representations substantially mediate emotional and behavioural responses. The common-sense model (CSM) posits that patients form idiosyncratic beliefs about their illness that guide coping and adjustment [120]. Across more than 300 studies grounded in the CSM, negative illness perceptions—conceiving the illness as chronic, uncontrollable, cyclical, symptom-laden or carrying severe consequences—associate robustly with depressive symptoms across diverse medical conditions [121]. These perceptions explain variance in depressive severity beyond objective indices of disease burden, indicating that subjective meaning and appraisal add explanatory value after controlling for clinical severity [122]. Symptom interpretation processes such as catastrophizing and threat-focused appraisals further amplify distress; interpreting ordinary bodily sensations as evidence of serious biological harm predisposes to persistent negative affect and maladaptive behavioural responses [123,124].



Figure-4: Attributed Psychological Factors.

Coping behaviours mediate the pathway from illness perceptions to outcome, though apparent inconsistencies in the literature reflect context dependence in the adaptiveness of particular strategies. Avoidance and denial can be momentarily adaptive during acute uncertainty—for instance when awaiting test results—but can become maladaptive when they impede necessary self-care or adherence to treatment. Empirical work indicates that avoidance and poor self-management correlate consistently with worse depressive outcomes across conditions [125]. By contrast, problem-focused coping and active engagement with treatment obligations generally support better psychological adjustment, though their effectiveness is moderated by the controllability of the stressor. Thus, the functional fit between coping strategy and situational demands determines whether coping protects against or potentiates depression. Protective psychological constructs warrant attention because they offer targets for intervention. Self-compassion, defined as a stance of kindness and

acceptance toward oneself amid suffering, supports adaptive coping and resilience in the face of illness [126]. Meta-analytic evidence links self-compassion to health-promoting behaviours and to reduced psychological distress; in chronic illness cohorts, including cancer populations, higher self-compassion correlates with lower depression levels [116,127,128,129]. Psychological flexibility, the capacity to modify behaviour and perspective in response to changing situational demands, similarly buffers against depression. Meta-analytic synthesis across a broad evidence base demonstrates lower psychological flexibility among individuals with depression and a robust association between inflexibility and greater depressive severity [130]. In medical populations, studies remain fewer, yet research in chronic pain indicates that diminished flexibility predicts future depression independently of pain intensity [131]. Cultivating flexibility and self-compassion may therefore reduce vulnerability to depression in medically ill patients by promoting adaptive appraisal, reducing rumination and encouraging engagement in valued activities despite symptom burden.

In summary, psychological pathways linking physical illness and depression operate through appraisal, coping and interpersonal processes that interact with personality traits and contextual factors. Illness-specific threats alter perceived controllability and future outlook. These appraisals bias attention toward somatic signals, fuel catastrophic interpretations and drive avoidance, thereby undermining adherence and social engagement and promoting depressive symptoms. Protective factors such as self-compassion and psychological flexibility mitigate these risks and represent plausible therapeutic targets. Future research should prioritize prospective modelling that integrates personality, illness perceptions, coping response profiles and social context to identify high-risk trajectories and to test psychological interventions tailored to the cognitive and behavioural patterns that sustain depression in medical populations.

Diagnosis, screening and prevention

Diagnosing major depressive disorder (MDD) in patients who have concurrent medical illnesses requires careful clinical judgment because somatic manifestations of physical disease frequently mimic the somatic criteria for MDD. Standard diagnostic frameworks such as the DSM-5 and ICD-10 remain the reference standards, yet both caution against attributing depressive diagnostic criteria to symptoms that are clearly more parsimoniously explained by a medical condition. Thus, clinicians must evaluate whether manifestations such as fatigue, appetite change, psychomotor slowing and sleep disturbance reflect primary mood pathology or are consequences of the underlying physical illness. By contrast, symptoms that are less likely to originate from medical disease—persistent depressed mood, pervasive feelings of worthlessness and active suicidal ideation—tend to point toward a primary depressive disorder rather than a purely medical explanation. The differential diagnosis must also consider other psychiatric syndromes that present depressive features, including bipolar spectrum disorders, and the option to code symptoms as a mood disorder secondary to a medical condition under DSM-5 or as an organic depressive disorder under ICD-10. Where diagnostic uncertainty persists, low-risk psychological interventions such as behavioural activation may be recommended because they carry minimal iatrogenic risk for medically ill patients and can improve mood and activity levels [132].

Assessment should also include routine evaluation for reversible medical contributors to depressive symptomatology. Basic laboratory tests for anemia, infection and thyroid dysfunction—typically haemoglobin, white blood cell count and thyroid-stimulating hormone—are reasonable prior steps before initiating antidepressant pharmacotherapy. Substance misuse requires systematic enquiry because alcohol and drug use can both mimic and mask depressive syndromes; the presence of substance misuse does not, however, rule out coexisting MDD and should prompt integrated management. Simple, pragmatic screening tools can facilitate case detection in general clinical settings. Two brief dichotomous questions about depressed mood and anhedonia function as a rapid screen; their high sensitivity renders a negative response to both items sufficient to exclude MDD in most cases, obviating further screening [134,135]. These two items are recommended in national guidance from multiple jurisdictions, including the WHO, the UK and Australia, though validation across all health system contexts, notably low- and middle-income countries, remains incomplete [136–138]. The PHQ-2, in its common multiple-choice format, should not be conflated with the binary two-question screen because the PHQ-2 exhibits different operating characteristics and, in some syntheses, weaker test performance [139–141]. Quantitatively, a positive response to either of the two dichotomous questions (score ≥ 1) yields very high sensitivity ($\approx 95\%$) and moderate specificity ($\approx 65\%$) for MDD, while a PHQ-2 score threshold of ≥ 2 produces slightly lower sensitivity and similar specificity [135,142]. Given the limited specificity of brief screens, positive results require confirmatory clinical assessment to determine whether diagnostic thresholds for MDD are met.

The nine-item Patient Health Questionnaire (PHQ-9) offers both screening and case-finding utility because it maps directly onto the DSM depressive symptom set and provides a continuous severity index. A cutoff of 10 or greater on the PHQ-9 provides a balance of sensitivity and specificity (pooled sensitivity $\approx 80\%$; pooled specificity $\approx 92\%$) and is commonly used to identify probable MDD [143,144]. Some clinical pathways use a stepped approach in

which an initial short screen is followed by the PHQ-9 for those who screen positive. Performance comparisons across these strategies vary; in meta-analytic work the PHQ-9 alone and the brief two-item binary questions can outperform combined algorithms in certain metrics, underscoring the need to select a screening approach that aligns with local priorities for sensitivity, specificity and available follow-up resources [145]. Screening frequency is not established by high-quality evidence. A pragmatic approach is to screen adults with medical illnesses at initial contact if they have not been screened previously, and to reassess patients at intervals determined by clinical risk factors, comorbidity profile and notable life events. Populations at elevated risk—such as pregnant and postpartum women, patients with progressive or disabling illnesses, and those with prior affective disorder—warrant closer surveillance.

Crucially, screening alone does not improve outcomes. Robust evidence demonstrates that depression detection yields patient benefit only when embedded within a collaborative care framework that includes a trained care manager and psychiatric consultation. In such models the care manager performs systematic case identification, provides patient education, implements behavioural activation, monitors symptoms and adherence, and oversees timely treatment adjustment. The consulting psychiatrist provides supervision and targeted medication or treatment recommendations. Trials of collaborative care show improved depression outcomes, but the model depends on infrastructure and workforce resources that may not be available in all settings, particularly in low-resource contexts [146,147]. Where collaborative care is not feasible, primary care settings remain the most appropriate venue for routine screening and management because they can integrate depression care with general medical follow up. Specialty clinics should consider screening only when they can provide or link patients to a reliable management pathway that includes case management and psychiatric support. In many specialty practices, outside oncology or dialysis services that sometimes function as de facto primary care—expecting routine depression screening and treatment without access to collaborative resources is not realistic and may yield limited benefit. Prevention strategies should therefore prioritize system design that links detection to evidence-based management. This includes clear referral pathways, access to behavioural interventions that pose low medical risk, timely psychiatric input for diagnostic clarification and medication management, and mechanisms to address modifiable contributors such as untreated hypothyroidism, anaemia or substance misuse. In resource-constrained environments innovative models of task sharing, remote consultation and stepped care merit evaluation because they may permit effective screening and management where specialist resources are sparse. Overall, diagnostic accuracy, judicious use of screening instruments, and the integration of detection into a coordinated care pathway constitute the foundation for preventing the adverse consequences of untreated comorbid depression in medical populations.

Management

The principles that guide treatment of major depressive disorder in general apply to depression that occurs alongside medical illness [1]. Treatment choice depends on the clinical severity and trajectory of both the medical disorder and the depressive episode. It also depends on patient preference, comorbidity, prior treatment response and the current medication regimen. Core treatment options include psychotherapy, pharmacotherapy, self-management strategies and optimization of the underlying medical disease. These options work best when delivered within an integrated care framework that coordinates medical, psychiatric and allied health input. Pain requires special consideration because it is a symptom that amplifies depressive risk; discussion of pain is provided separately (Box 5). Severe presentations such as psychotic depression or treatment-resistant depression demand specialist pathways and are addressed in other focused reviews of MDD [1]. The summary below outlines key practical considerations for pharmacological, psychotherapeutic, neuromodulatory and system-level approaches to management of comorbid depression. Pharmacotherapy decisions must balance efficacy against safety in the context of the patient's medical conditions and concurrent treatments. Choice of agent should take into account age, presence of pain, degree of polypharmacy, severity and course of the depressive episode, prior antidepressant trials and likely drug–drug interactions.

Efficacy evidence for antidepressants in medically ill populations shows mixed results. Trials in unselected MDD report low to moderate effect sizes, with standardized mean differences (SMDs) typically in the range 0.17–0.49 [148]. Some meta-analyses focused on comorbid depression in defined medical disorders report larger treatment effects. One synthesis reported an SMD of 0.66 and an NNT of 6 for antidepressant treatment in medical populations, with clearer signals in coronary heart disease, cancer, type 2 diabetes and selected neurological disorders including post-stroke depression, Parkinson disease and multiple sclerosis [149–156] (Table 1). These larger estimates may reflect lower placebo responses, synergistic biological interactions between antidepressants and disease processes, or publication bias. Other meta-analyses find smaller or absent effects. For example, data in cancer and rheumatoid arthritis are mixed, while evidence in inflammatory bowel disease remains insufficient [157–159]. Many trials were small and of variable quality, and pooled estimates must be interpreted with caution. Overall,

antidepressants can be effective in patients with medical comorbidity, but robust, adequately powered randomized trials remain limited. Safety is a central concern. Drug–drug interactions arise from direct pharmacodynamic interactions and from pharmacokinetic effects mediated by renal excretion or hepatic metabolism. The hepatic cytochrome P450 superfamily, including isoenzymes such as CYP2D6 and CYP3A4, metabolizes a large proportion of prescribed drugs [160]. Pharmacogenomic testing can identify individuals who are rapid or slow metabolizers and preliminary evidence suggests testing may improve response and remission rates in depression [161]. Clinicians should consult drug interaction resources when planning treatment. Mobile applications and online databases such as MedScape, GenieMD and CVS Caremark provide rapid access to interaction checks for many drugs [162,163].

Specific adverse effect profiles guide agent selection. Tricyclic antidepressants and monoamine oxidase inhibitors carry established cardiotoxic risk and should be avoided in patients with significant cardiac disease [165,166]. Selective serotonin reuptake inhibitors, particularly sertraline, have a lower cardiotoxic profile and are often preferred in cardiac populations [167]. QTc prolongation is a concern with some antidepressants. TCAs show higher rates of QTc prolongation than SSRIs in pooled analyses [168]. Certain SSRIs, notably escitalopram and citalopram, also prolong QTc and require caution, especially when co-prescribed with other QTc-prolonging agents such as some antibiotics and antiarrhythmic drugs [168,169]. When such co-prescriptions are unavoidable clinicians should monitor the QTc interval closely. Pharmacokinetic interactions can alter levels of cardiovascular agents. Some SSRIs increase plasma concentrations of calcium channel blockers and beta blockers, necessitating dosage review and monitoring [170]. Conversely, SSRIs appear safe to combine with statins and renin–angiotensin system drugs and may even associate with improved mood outcomes in observational data [171]. Statins have been proposed to exert mood benefits through anti-inflammatory and neuroplastic mechanisms, although most mechanistic data are preclinical [172]. SSRIs inhibit platelet serotonin uptake, a mechanism that increases bleeding risk. Concomitant NSAID or aspirin use amplifies this risk; proton pump inhibitor co-prescription reduces gastrointestinal bleeding risk [173]. Warfarin interactions with some antidepressants can raise warfarin levels, requiring closer INR surveillance [174].

Metabolic effects also inform selection. Antidepressant treatment has been associated with modest increases in risk for type 2 diabetes in some epidemiological studies [175]. Weight gain is a known adverse effect of certain agents, most notably TCAs and mirtazapine; monitoring of weight, glucose and lipids is prudent after initiation [176]. Long-term antidepressant exposure and medical disease may each influence bone metabolism; SSRIs and some medical drugs have been associated with altered bone density and increased fracture risk. Patients at high risk of osteoporosis should have bone density assessment when long-term therapy is planned [178,179]. Some antidepressants lower seizure threshold: agents such as bupropion and some SSRIs carry small seizure risks that are generally low in people with well-controlled epilepsy but require caution [180]. Anticonvulsant co-therapy can alter antidepressant levels; for example, carbamazepine may reduce TCA concentrations whereas valproate may increase them, prompting dosage adjustments [181]. Combining sedating antidepressants with central nervous system depressants may increase sedation and impair cognition [182].

Treating the underlying medical disease can itself affect depressive symptoms. Successful management of the somatic illness may reduce depressive burden by lowering inflammatory activity, relieving pain, reducing functional impairment, and improving perceived prognosis. Biological therapies that modulate cytokines illustrate this point. Trials of cytokine inhibitors such as anti-IL-6 and anti-IL-12/IL-23 agents in inflammatory disorders have reported reductions in depressive symptoms that appear at least partly independent of improvements in pain or other disease symptoms, supporting a direct role of immune modulation in mood regulation [72,73]. Nonetheless, immune-modulating agents are not standard treatments for primary MDD. In multiple sclerosis disease-modifying therapies have not demonstrated increased depression risk overall, and some agents such as fingolimod have been associated with mood improvement in pooled analyses [183]. In Parkinson disease guidelines recommend optimizing dopaminergic therapy as a first step for depressive symptoms, with antidepressants added when depressive symptoms persist despite adequate dopaminergic treatment [184]. Psychotherapy adapts to the realities of medical illness. Treatment aims typically include symptom reduction, reinforcement of coping skills, restoration of function and support for illness-related adjustment. Psychotherapy in medically ill patients must account for limited time windows, fluctuating capacity, treatment burden and comorbidity. Clinicians delivering psychotherapy in medical settings require knowledge of common treatments and adverse effects, and close collaboration with the medical team.

Supportive, cognitive and behavioural approaches are common and often integrate psychoeducation, problem solving, emotion regulation, relaxation, mindfulness and meaning-focused techniques. Interventions may be delivered individually to couples or in groups. Trials in cancer populations that enrolled patients with elevated distress report a moderate pooled effect size for psychological interventions on post-treatment

depression measures (d ≈ 0.53) across approaches such as CBT, supportive–expressive therapy, relaxation and psychoeducation [186]. In advanced cancer populations psychotherapy shows moderate improvements in depressive scores versus control conditions with pooled SMDs around 0.67 [187]. Longer duration treatments generally yield larger sustained effects, often beyond six months [186]. Most trials have focused on breast cancer cohorts; evidence in other tumour groups is sparser and trials often rely on self-report measures rather than structured diagnostic interviews. Screening instruments such as the HADS and the PHQ-9 may produce false positives in cancer settings and can overestimate clinical depression when applied with sensitive cut points [190]. Benefits of psychotherapy extend to other medical conditions. CBT has demonstrated efficacy for post-stroke depression in some meta-analyses with pooled SMDs suggesting clinically meaningful effects [191]. Other syntheses show benefit of CBT and mindfulness-based interventions in Parkinson disease and multiple sclerosis [193,194]. Trials in cardiovascular disease and diabetes report variable but often positive effects for CBT on depressive outcomes [195,196]. Heterogeneity in effect estimates often reflects trial quality. Methodological limitations common in this literature include small samples, lack of allocation concealment, inadequate blinding, selective reporting and incomplete follow-up due to disease progression [186,187]. Many psychotherapy trials use non-active controls such as waitlists, which can exaggerate effect sizes [199]. Third-wave therapies such as acceptance and commitment therapy show emerging promise in medical populations including cancer and epilepsy [198].

Neurostimulation has a defined role for severe presentations. Electroconvulsive therapy (ECT) remains the treatment of choice for severe, psychotic or treatment-refractory depression and for depression with acute suicidality [200,201]. Older age and greater baseline severity predict better ECT response [202]. Cognitive adverse effects are the most frequent concern, but objective deficits appear to be short lived for many domains, with recovery and improvements beyond baseline by two weeks on some measures [203]. ECT should be reserved for severe cases or after failure of multiple trials of other modalities. Repetitive transcranial magnetic stimulation and transcranial direct current stimulation have demonstrated efficacy and tolerability in network meta-analysis and may offer alternatives where ECT is unsuitable [204]. Data specific to medically ill populations are growing but remain limited. Integrated care models maximize the benefit of screening and treatment. Collaborative care frameworks that embed a trained care manager and psychiatric consultation within primary care produce consistent improvements in depression outcomes. The care manager conducts systematic monitoring, delivers behavioural activation, supports adherence, and facilitates timely escalation for non-response. The consulting psychiatrist supervises the care manager, provides diagnostic clarification and recommends medication adjustments. Trials of collaborative care show improved remission rates and functional outcomes, but implementation requires workforce and system resources that may be scarce in low-resource settings. Task-sharing, stepped care, telepsychiatry and digital interventions provide scalable alternatives that merit rigorous evaluation.

Self-management and lifestyle interventions serve as adjuncts. Promoting physical activity, smoking cessation, moderation of alcohol use, sleep hygiene, structured problem solving and social activation can improve mood and may reduce somatic risk. Nutritional support, sleep stabilization and graded exercise have specific evidence for mood benefits in some populations. Clinicians should integrate behavioural counselling and refer to allied professionals where available. Monitoring and follow-up are essential. Antidepressant response typically requires 4–8 weeks for initial effect and longer for full remission. Clinicians should set measurable targets, monitor adverse effects, assess adherence, review interactions with medical therapies and adjust treatment promptly for partial or non-response. Use of validated scales such as the PHQ-9 supports objective tracking of symptoms over time. Special populations require tailored approaches. Older adults, pregnant and postpartum women, patients with cognitive impairment and those with severe medical frailty need individualized risk–benefit assessment for pharmacological and psychotherapeutic interventions. Coordination with specialties such as obstetrics, neurology, cardiology and oncology ensures safe and effective care. Research priorities include adequately powered randomized trials of antidepressants and psychotherapies in defined medical populations, mechanistic studies that link biological targets to treatment response, and implementation research on scalable models of integrated care. Trials should use standardized case definitions, structured diagnostic interviews, and rigorous outcome measures that include functional recovery and quality of life. In summary, management of comorbid depression requires a multifaceted strategy. Pharmacological and psychological therapies have demonstrated benefit in many settings, but choice and delivery must account for medical comorbidity, drug interactions and patient capacity. Neuromodulation remains a critical option for severe cases. Integrated care models that link detection to active management yield the greatest population benefit. Clinicians should monitor treatment closely, address modifiable contributors and collaborate across specialties to provide coherent, patient-centered care.

Role of Psychologists, Socialists, Nursing, and Health Information Workers:

Psychologists play a central role in the identification and treatment of depression in patients with medical illness. They conduct diagnostic assessments that differentiate primary mood disorder from illness related somatic symptoms. They deliver evidence based psychotherapies such as cognitive behavioral therapy and acceptance and commitment therapy that target maladaptive illness beliefs, catastrophic appraisal and avoidance. Psychologists design brief interventions that fit within constrained clinical windows, and they adapt therapy to fluctuations in physical capacity. They measure outcomes with validated instruments and use those data to guide iterative treatment planning. They also provide training to medical teams on communication strategies, behavioral activation techniques and approaches to enhance adherence. Social workers address the social determinants that influence both onset and course of depression in medically ill populations. They assess social resources, financial barriers and family dynamics that affect access to care and capacity for self-management. Social workers coordinate community based services, arrange home care and liaise with insurance and welfare systems to reduce practical impediments to treatment. They provide short term counseling that focuses on problem solving and resource mobilization. They also participate in care planning meetings and advocate for patient centered modifications to treatment schedules and discharge plans that reflect social constraints.



Figure-5: Interdisciplinary care of comorbid depression.

Nurses provide continuous clinical contact that positions them to detect early signs of depressive deterioration and to implement basic psychosocial interventions. They perform routine screening, monitor symptom trajectories and report changes to the treating team. Nurses deliver psychoeducation on the interaction between medical treatment and mood, coach patients in medication adherence and behavioral activation and support sleep hygiene and activity pacing. They manage somatic symptoms that can mimic depression, and they coordinate referrals to mental health professionals. In integrated care models nurses often assume the role of care manager. In that role they track outcomes, provide brief therapeutic contacts and ensure timely treatment adjustments. Health information workers create and maintain the informational infrastructure that enables multidisciplinary care for comorbid depression. They design electronic health record templates that capture screening results, diagnostic codes, treatment plans and outcome measures. They enable systematic case finding through registries and automated alerts for patients who meet high risk criteria. They ensure secure data exchange across specialties and community services to support continuity of care. Health information workers also analyze service use and outcome data to inform quality improvement and to demonstrate the value of integrated depression care in medical settings.

Interdisciplinary collaboration multiplies the effect of each discipline. Psychologists, social workers and nurses meet regularly to review high risk cases and to align behavioral interventions with medical treatment plans. Health information workers provide the data feeds that make these meetings efficient, and evidence driven. Clear role delineation reduces duplication and ensures that tasks such as screening, diagnostic confirmation and ongoing monitoring occur in the most appropriate setting. Joint protocols for stepped care, crisis response and escalation of treatment support patient safety and reduce delays in care. Workforce training and capacity building sustain these roles. Psychologists can train nurses and social workers in core therapeutic techniques that broaden access to effective interventions. Social workers can train clinical teams in resource navigation and discharge planning. Health information specialists can deliver training on documentation standards and use of decision support tools. Regular cross disciplinary education fosters shared language and consistent application of evidence based pathways. Performance measurement and implementation science are essential for scale. Teams should track process indicators such as screening rates, referral completion and time to treatment initiation. They should track outcome indicators such as symptom reduction, functional recovery and readmission rates. Health information workers enable this surveillance and produce reports that guide iterative service redesign. Research that tests models of task sharing, stepped care and telehealth in diverse clinical settings will clarify which configurations deliver the best outcomes for patients with comorbid depression and medical illness.

Conclusion:

In conclusion, the effective management of depression in patients with chronic medical conditions demands an integrated, multi-pronged strategy that addresses their complex interplay. Simply detecting depression is insufficient; success requires a systematic, collaborative care framework that actively links screening to evidence-based treatment. This approach must judiciously combine pharmacological interventions, chosen for their safety profile and minimal interaction with somatic treatments, with psychotherapies adapted to the realities of physical illness. Crucially, the roles of psychologists, social workers, nurses, and health information specialists are fundamental, providing a coordinated support system that addresses the biological, psychological, and social dimensions of comorbidity. Ultimately, overcoming

the siloed separation of mental and physical healthcare is paramount. By implementing patient-centered, multidisciplinary models, clinicians can significantly improve both mental health outcomes and the overall trajectory of chronic medical disease, enhancing quality of life and functional recovery.

References:

1. Otte, C. et al. Major depressive disorder. *Nat. Rev. Dis. Prim.* **2**, 16065 (2016).
2. Whiteford, H. A. et al. Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. *Lancet* **382**, 1575–1586 (2013).
3. Moussavi, S. et al. Depression, chronic diseases, and decrements in health: results from the world health surveys. *Lancet* **370**, 851–858 (2007).
4. Puyat, J. H., Kazanjian, A., Wong, H. & Goldner, E. Comorbid chronic general health conditions and depression care: a population-based analysis. *Psychiatr. Serv.* **68**, 907–915 (2017).
5. Gonzalez, J. S. et al. Depression and diabetes treatment nonadherence: a meta-analysis. *Diabetes Care* **31**, 2398–2403 (2008).
6. Pelletier, G., Verhoef, M. J., Khatri, N. & Hagen, N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. *J. Neurooncol.* **57**, 41–49 (2002).
7. Suppli, N. P. et al. Survival after early-stage breast cancer of women previously treated for depression: a nationwide Danish cohort study. *J. Clin. Oncol.* **35**, 334–342 (2017).
8. Rutledge, T., Reis, V. A., Linke, S. E., Greenberg, B. H. & Mills, P. J. Depression in heart failure. *J. Am. Coll. Cardiol.* **48**, 1527–1537 (2006).
9. Koyanagi, A. et al. Mortality in unipolar depression preceding and following chronic somatic diseases. *Acta Psychiatr. Scand.* **138**, 500–508 (2018).
10. Cai, W., Mueller, C., Li, Y.-J., Shen, W.-D. & Stewart, R. Post stroke depression and risk of stroke recurrence and mortality: a systematic review and meta-
11. Momen, N. C. et al. Association between mental disorders and subsequent medical conditions. *N. Engl. J. Med.* **382**, 1721–1731 (2020).
12. Plana-Ripoll, O. et al. A comprehensive analysis of mortality-related health metrics associated with mental disorders: a nationwide, register-based cohort study. *Lancet* **394**, 1827–1835 (2019).
13. Plana-Ripoll, O. et al. Changes over time in the differential mortality gap in individuals with mental disorders. *JAMA Psychiatry* **77**, 648–650 (2020).
14. Machado, M. O. et al. The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses. *BMC Med.* **16**, 112 (2018).
15. Roest, A. M. & de Jonge, P. The heart of the matter: in search of causal effects of depression on somatic diseases. *BMC Med.* **16**, 147 (2018).
16. Ferrari, A. J. et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. *Psychol. Med.* **43**, 471–481 (2013).
17. Vos, T. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* **390**, 1211–1259 (2017).
18. Pedersen, C. B. et al. A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. *JAMA Psychiatry* **71**, 573–581 (2014).
19. Salk, R. H., Hyde, J. S. & Abramson, L. Y. Gender differences in depression in representative national samples: meta-analyses of diagnoses and symptoms. *Psychol. Bull.* **143**, 783–822 (2017).
20. Luppa, M. et al. Age- and gender-specific prevalence of depression in latest-life – systematic review and meta-analysis. *J. Affect. Disord.* **136**, 212–221 (2012).
21. Sjöberg, L. et al. Prevalence of depression: comparisons of different depression definitions in population-based samples of older adults. *J. Affect. Disord.* **221**, 123–131 (2017).
22. Walker, J. et al. The prevalence of depression in general hospital inpatients: a systematic review and meta-analysis of interview-based studies. *Psychol. Med.* **48**, 2285–2298 (2018).
23. Wang, J. et al. Prevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysis. *BMJ Open* **7**, e017173 (2017).
24. Mitchell, A. J. et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. *Lancet Oncol.* **12**, 160–174 (2011).
25. Krebber, A. M. H. et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. *Psychooncology* **23**, 121–130 (2013).
26. Watts, S. et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. *BMJ Open* **4**, e003901 (2014).
27. Watts, S., Prescott, P., Mason, J., McLeod, N. & Lewith, G. Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates. *BMJ Open* **5**, e007618 (2015).
28. Huang, J. et al. Association between depression and brain tumor: a systematic review and meta-analysis. *Oncotarget* **8**, 94932–94943 (2017).

29. Mehnert, A. et al. Four-week prevalence of mental disorders in patients with cancer across major tumor entities. *J. Clin. Oncol.* **32**, 3540–3546 (2014).
30. Secinti, E., Thompson, E. J., Richards, M. & Gaysina, D. Research review: childhood chronic physical illness and adult emotional health – a systematic review and meta-analysis. *J. Child. Psychol. Psychiatry* **58**, 753–769 (2017).
31. Freedland, K. E. et al. Prevalence of depression in hospitalized patients with congestive heart failure. *Psychosom. Med.* **65**, 119–128 (2003).
32. Brostow, D. P., Petrik, M. L., Starosta, A. J. & Waldo, S. W. Depression in patients with peripheral arterial disease: a systematic review. *Eur. J. Cardiovasc. Nurs.* **16**, 181–193 (2017).
33. Feng, L. et al. Prevalence of depression in myocardial infarction. *Medicine* **98**, e14596 (2019).
34. Doyle, F. et al. Systematic review and individual patient data meta-analysis of sex differences in depression and prognosis in persons with myocardial infarction. *Psychosom. Med.* **77**, 419–428 (2015).
35. Khaledi, M., Haghighatdoost, F., Feizi, A. & Aminorroaya, A. The prevalence of comorbid depression in patients with type 2 diabetes: an updated systematic review and meta-analysis on huge number of observational studies. *Acta Diabetol.* **56**, 631–650 (2019).
36. Barnard, K. D., Skinner, T. C. & Peveler, R. The prevalence of co-morbid depression in adults with type 1 diabetes: systematic literature review. *Diabet. Med.* **23**, 445–448 (2006).
37. Buchberger, B. et al. Symptoms of depression and anxiety in youth with type 1 diabetes: a systematic review and meta-analysis. *Psychoneuroendocrinology* **70**, 70–84 (2016).
38. Cooney, L. G., Lee, I., Sammel, M. D. & Dokras, A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. *Hum. Reprod.* **32**, 1075–1091 (2017).
39. Mitchell, A. J. et al. Prevalence and predictors of post-stroke mood disorders: a meta-analysis and meta-regression of depression, anxiety and adjustment disorder. *Gen. Hosp. Psychiatry* **47**, 48–60 (2017).
40. Ayerbe, L., Ayis, S., Wolfe, C. D. A. & Rudd, A. G. Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. *Br. J. Psychiatry* **202**, 14–21 (2013).
41. Boeschoten, R. E. et al. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. *J. Neurol. Sci.* **372**, 331–341 (2017).
42. Marrie, R. A. et al. Differences in the burden of psychiatric comorbidity in MS vs the general population. *Neurology* **85**, 1972–1979 (2015).
43. McKay, K. A. et al. Psychiatric comorbidity is associated with disability progression in multiple sclerosis. *Neurology* **90**, e1316–e1323 (2018).
44. Binzer, S., McKay, K. A., Brenner, P., Hillert, J. & Manouchehrinia, A. Disability worsening among persons with multiple sclerosis and depression: a Swedish cohort study. *Neurology* **93**, e2216–e2223 (2019).
45. Kim, M., Kim, Y.-S., Kim, D.-H., Yang, T.-W. & Kwon, O.-Y. Major depressive disorder in epilepsy clinics: a meta-analysis. *Epilepsy Behav.* **84**, 56–69 (2018).
46. Goodarzi, Z. et al. Detecting depression in Parkinson disease. *Neurology* **87**, 426–437 (2016).
47. Chi, S. et al. The prevalence of depression in Alzheimer's disease: a systematic review and meta-analysis. *Curr. Alzheimer Res.* **12**, 189–198 (2015).
48. Zhang, L., Fu, T., Yin, R., Zhang, Q. & Shen, B. Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis. *BMC Psychiatry* **17**, 70 (2017).
49. Dowlatshahi, E. A., Wakkee, M., Arends, L. R. & Nijsten, T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. *J. Investig. Dermatol.* **134**, 1542–1551 (2014).
50. Matcham, F., Rayner, L., Steer, S. & Hotopf, M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. *Rheumatology* **52**, 2136–2148 (2013).
51. Neuendorf, R., Harding, A., Stello, N., Hanes, D. & Wahbeh, H. Depression and anxiety in patients with inflammatory bowel disease: a systematic review. *J. Psychosom. Res.* **87**, 70–80 (2016).
52. Mulugeta, A., Zhou, A., King, C. & Hyppönen, E. Association between major depressive disorder and multiple disease outcomes: a phenome-wide Mendelian randomisation study in the UK Biobank. *Mol. Psychiatry* **25**, 1469–1476 (2019).
53. Tylee, D. S. et al. Genetic correlations among psychiatric and immune-related phenotypes based on genome-wide association data. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* **177**, 641–657 (2018).
54. Tyrrell, J. et al. Using genetics to understand the causal influence of higher BMI on depression. *Int. J. Epidemiol.* **48**, 834–848 (2019).
55. Milaneschi, Y. et al. Genetic association of major depression with atypical features and obesity-related immunometabolic dysregulations. *JAMA Psychiatry* **74**, 1214–1225 (2017).
56. Haljas, K. et al. Bivariate genome-wide association study of depressive symptoms with

type 2 diabetes and quantitative glycemic traits. *Psychosom. Med.* **80**, 242–251 (2018).
57. Samaan, Z. et al. Lack of association between type 2 diabetes and major depression: epidemiologic and genetic evidence in a multiethnic population. *Transl Psychiatry* **5**, e618 (2015).
58. Clarke, T.-K. et al. Investigating shared aetiology between type 2 diabetes and major depressive disorder in a population based cohort. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* **174**, 227–234 (2016).
59. Khandaker, G. M. et al. Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort. *Mol. Psychiatry* **25**, 1477–1486 (2020).
60. Brainstorm Consortium. et al. Analysis of shared heritability in common disorders of the brain. *Science* **360**, eaap8757 (2018).
61. Wang, J. S. et al. Examining the effect of 5-HTTLPR on depressive symptoms in postmenopausal women 1 year after initial breast cancer treatment. *Support. Care Cancer* **27**, 513–519 (2019).
62. Ogrodnik, M. et al. Obesity-induced cellular senescence drives anxiety and impairs neurogenesis. *Cell Metab.* **29**, 1061–1077 (2019).
63. Kennis, M. et al. Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis. *Mol. Psychiatry* **25**, 321–338 (2019).
64. Otte, C., Neylan, T. C., Pipkin, S. S., Browner, W. S. & Whooley, M. A. Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul study. *Am. J. Psychiatry* **162**, 2139–2145 (2005).
65. Otte, C. et al. Depression and 24-hour urinary cortisol in medical outpatients with coronary heart disease: the Heart and Soul study. *Biol. Psychiatry* **56**, 241–247 (2004).
66. Enache, D., Pariante, C. M. & Mondelli, V. Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. *Brain Behav. Immun.* **81**, 24–40 (2019).
67. Köhler, C. A. et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. *Acta Psychiatr. Scand.* **135**, 373–387 (2017).
68. Osimo, E. F., Baxter, L. J., Lewis, G., Jones, P. B. & Khandaker, G. M. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. *Psychol. Med.* **49**, 1958–1970 (2019).
69. Orlovska-Waast, S. et al. Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. *Mol. Psychiatry* **24**, 869–887 (2018).
70. Hodes, G. E., Kana, V., Menard, C., Merad, M. & Russo, S. J. Neuroimmune mechanisms of depression. *Nat. Neurosci.* **18**, 1386–1393 (2015).
71. Nerurkar, L., Siebert, S., McInnes, I. B. & Cavanagh, J. Rheumatoid arthritis and depression: an inflammatory perspective. *Lancet Psychiatry* **6**, 164–173 (2019).
72. Kappelmann, N., Lewis, G., Dantzer, R., Jones, P. B. & Khandaker, G. M. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. *Mol. Psychiatry* **23**, 335–343 (2016).
73. Wittenberg, G. M. et al. Effects of immunomodulatory drugs on depressive symptoms: a mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders. *Mol. Psychiatry* **25**, 1275–1285 (2019).
74. Duivis, H. E. et al. Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the Heart and Soul study. *Am. J. Psychiatry* **168**, 913–920 (2011).
75. Laake, J.-P. S. et al. The association between depressive symptoms and systemic inflammation in people with type 2 diabetes: findings from the South London Diabetes Study. *Diabetes Care* **37**, 2186–2192 (2014).
76. Hayashino, Y., Mashitani, T., Tsujii, S. & Ishii, H. Elevated levels of hs-CRP are associated with high prevalence of depression in Japanese patients with type 2 diabetes: the Diabetes Distress and Care Registry at Tenri (DDCRT 6). *Diabetes Care* **37**, 2459–2465 (2014).
77. Moulton, C. D., Pickup, J. C. & Ismail, K. The link between depression and diabetes: the search for shared mechanisms. *Lancet Diabetes Endocrinol.* **3**, 461–471 (2015).
78. Carson, A. J. et al. Depression after stroke and lesion location: a systematic review. *Lancet* **356**, 122–126 (2000).
79. Wei, N. et al. Post-stroke depression and lesion location: a systematic review. *J. Neurol.* **262**, 81–90 (2014).
80. Padmanabhan, J. L. et al. A human depression circuit derived from focal brain lesions. *Biol. Psychiatry* **86**, 749–758 (2019).
81. Allida, S. et al. Pharmacological, psychological, and non-invasive brain stimulation interventions for treating depression after stroke. *Cochrane Database Syst. Rev.* **1**, CD0033437 (2020).
82. Gold, S. M. et al. Detection of altered hippocampal morphology in multiple sclerosis-associated depression using automated surface mesh modeling. *Hum. Brain Mapp.* **35**, 30–37 (2012).

83. Rossi, S. et al. Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis. *Neurology* **89**, 1338–1347 (2017).
84. Corallo, F. et al. A complex relation between depression and multiple sclerosis: a descriptive review. *Neurol. Sci.* **40**, 1551–1558 (2019).
85. Qato, D. M., Ozenberger, K. & Olfson, M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. *JAMA* **319**, 2289–2298 (2018).
86. Verbeek, D. E. P., van Riezen, J., de Boer, R. A., van Melle, J. P. & de Jonge, P. A review on the putative association between beta-blockers and depression. *Heart Fail. Clin.* **7**, 89–99 (2011).
87. Salagre, E., Fernandes, B. S., Dodd, S., Brownstein, D. J. & Berk, M. Statins for the treatment of depression: a meta-analysis of randomized, double-blind, placebo-controlled trials. *J. Affect. Disord.* **200**, 235–242 (2016).
88. Kovacs, D., Kovacs, P., Eszlari, N., Gonda, X. & Juhasz, G. Psychological side effects of immune therapies: symptoms and pathomechanism. *Curr. Opin. Pharmacol.* **29**, 97–103 (2016).
89. Udina, M. et al. Interferon-induced depression in chronic hepatitis C. *J. Clin. Psychiatry* **73**, 1128–1138 (2012).
90. Schaefer, M. et al. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. *Ann. Intern. Med.* **157**, 94–103 (2012).
91. Mann, T. K., Dail, R. B. & Bailey, D. E. Cognitive and affective symptoms experienced by cancer patients receiving high-dose intravenous interleukin 2 therapy: an integrative literature review. *Cancer Nurs.* **39**, 349–357 (2016).
92. DellaGioia, N. & Hannestad, J. A critical review of human endotoxin administration as an experimental paradigm of depression. *Neurosci. Biobehav. Rev.* **34**, 130–143 (2010).
93. Weinberger, A. H. et al. Depression and cigarette smoking behavior: a critical review of population-based studies. *Am. J. Drug. Alcohol. Abuse* **43**, 416–431 (2016).
94. Forouzanfar, M. H. et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* **388**, 1659–1724 (2016).
95. Chauhan, G. et al. Genetic and lifestyle risk factors for MRI-defined brain infarcts in a population-based setting. *Neurology* **92**, e486–e503 (2019).
96. Belbasis, L., Bellou, V., Evangelou, E., Ioannidis, J. P. A. & Tzoulaki, I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. *Lancet Neurol.* **14**, 263–273 (2015).
97. Chaiton, M. O., Cohen, J. E., OtextquotesingleLoughlin, J. & Rehm, J. A systematic review of longitudinal studies on the association between depression and smoking in adolescents. *BMC Public. Health* **9**, 356 (2009).
98. Ho, S. Y., Alnashri, N., Rohde, D., Murphy, P. & Doyle, F. Systematic review and meta-analysis of the impact of depression on subsequent smoking cessation in patients with chronic respiratory conditions. *Gen. Hosp. Psychiatry* **37**, 399–407 (2015).
99. Patten, S. B., Williams, J. V. & Bulloch, A. G. Major depressive episodes and mortality in the Canadian household population. *J. Affect. Disord.* **242**, 165–171 (2019).
100. Choi, K. W. et al. Assessment of bidirectional relationships between physical activity and depression among adults. *JAMA Psychiatry* **76**, 399–408 (2019).
101. Whooley, M. A. et al. Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. *JAMA* **300**, 2379–2388 (2008).
102. Boden, J. M. & Fergusson, D. M. Alcohol and depression. *Addiction* **106**, 906–914 (2011).
103. Lassale, C. et al. Healthy dietary indices and risk of depressive outcomes: a systematic review and meta-analysis of observational studies. *Mol. Psychiatry* **24**, 965–986 (2018).
104. Molendijk, M., Molero, P., Ortuño Sánchez-Pedreño, F., Van der Does, W. & Angel Martínez-González, M. Diet quality and depression risk: a systematic review and dose-response meta-analysis of prospective studies. *J. Affect. Disord.* **226**, 346–354 (2018).
105. Martínez-González, M. A., Gea, A. & Ruiz-Canela, M. The Mediterranean diet and cardiovascular health. *Circulation Res.* **124**, 779–798 (2019).
106. Bot, M. et al. Effect of multinutrient supplementation and food-related behavioral activation therapy on prevention of major depressive disorder among overweight or obese adults with subsyndromal depressive symptoms. *JAMA* **321**, 858–868 (2019).
107. Mausbach, B. T., Schwab, R. B. & Irwin, S. A. Depression as a predictor of adherence to adjuvant endocrine therapy (AET) in women with breast cancer: a systematic review and meta-analysis. *Breast Cancer Res. Treat.* **152**, 239–246 (2015).
108. Kessing, D., Denollet, J., Widdershoven, J. & Kupper, N. Psychological determinants of heart failure self-care. *Psychosom. Med.* **78**, 412–431 (2016).
109. Brown, S. A. et al. Biobehavioral determinants of glycemic control in type 2 diabetes: a systematic review and meta-analysis. *Patient Educ. Couns.* **99**, 1558–1567 (2016).

110. Rieckmann, N. et al. Course of depressive symptoms and medication adherence after acute coronary syndromes. *J. Am. Coll. Cardiol.* **48**, 2218–2222 (2006).
111. Folkman, S. in *Encyclopedia of Behavioral Medicine* (eds Gellman, M. D. & Turner, J. R.) 1913–1915 (Springer, 2013).
112. Heijmans, M. et al. The stress of being chronically ill: from disease-specific to task-specific aspects. *J. Behav. Med.* **27**, 255–271 (2004).
113. Moss-Morris, R. Adjusting to chronic illness: time for a unified theory. *Br. J. Health Psychol.* **18**, 681–686 (2013).
114. Clarke, D. M. & Currie, K. C. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. *Med. J. Aust.* **190**, S54–S60 (2009).
115. Detweiler-Bedell, J. B., Friedman, M. A., Leventhal, H., Miller, I. W. & Leventhal, E. A. Integrating co-morbid depression and chronic physical disease management: identifying and resolving failures in self-regulation. *Clin. Psychol. Rev.* **28**, 1426–1446 (2008).
116. Sirois, F. M., Kitner, R. & Hirsch, J. K. Self-compassion, affect, and health-promoting behaviors. *Health Psychol.* **34**, 661–669 (2015).
117. Schiavon, C. C., Marchetti, E., Gurgel, L. G., Busnello, F. M. & Reppold, C. T. Optimism and hope in chronic disease: a systematic review. *Front. Psychol.* **7**, 2022 (2016).
118. Leventhal, H., Diefenbach, M. & Leventhal, E. A. Illness cognition: using common sense to understand treatment adherence and affect cognition interactions. *Cognit. Ther. Res.* **16**, 143–163 (1992).
119. Trudel-Fitzgerald, C. et al. The relationship of perfectionism with psychological symptoms in cancer patients and the contributing role of hyperarousability and coping. *Psychol. Health* **32**, 381–401 (2017).
120. Leventhal, H., Brissette, I. & Leventhal, E. A. in *The Self-regulation of Health and Illness Behaviour* (eds Cameron, L. D. & Leventhal, H.) 42–65 (Psychology Press, 2003).
121. Hagger, M. S., Koch, S., Chatzisarantis, N. L. D. & Orbell, S. The common sense model of self-regulation: meta-analysis and test of a process model. *Psychol. Bull.* **143**, 1117–1154 (2017).
122. Uhlenbusch, N. et al. Depression and anxiety in patients with different rare chronic diseases: a cross-sectional study. *PLoS ONE* **14**, e0211343 (2019).
123. Edwards, R. R., Cahalan, C., Mensing, G., Smith, M. & Haythornthwaite, J. A. Pain, catastrophizing, and depression in the rheumatic diseases. *Nat. Rev. Rheumatol.* **7**, 216–224 (2011).
124. Edwards, R. R., Bingham, C. O., Bathon, J. & Haythornthwaite, J. A. Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. *Arthritis Rheum.* **55**, 325–332 (2006).
125. Hudson, J. L. & Moss-Morris, R. Treating illness distress in chronic illness. *Eur. Psychol.* **24**, 26–37 (2019).
126. Neff, K. Self-compassion: an alternative conceptualization of a healthy attitude toward oneself. *Self Identity* **2**, 85–101 (2003).
127. Pinto-Gouveia, J., Duarte, C., Matos, M. & Fráguas, S. The protective role of self-compassion in relation to psychopathology symptoms and quality of life in chronic and in cancer patients. *Clin. Psychol. Psychother.* **21**, 311–323 (2013).
128. Przezdziecki, A. et al. My changed body: breast cancer, body image, distress and self-compassion. *Psychooncology* **22**, 1872–1879 (2012).
129. Sirois, F. M. & Rowse, G. The role of self-compassion in chronic illness care. *J. Clin. Outcome Manag.* **23**, 521–527 (2016).
130. Stange, J. P., Alloy, L. B. & Fresco, D. M. Inflexibility as a vulnerability to depression: a systematic qualitative review. *Clin. Psychol. Sci. Pract.* **24**, 245–276 (2017).
131. Gentili, C. et al. Psychological flexibility as a resilience factor in individuals with chronic pain. *Front. Psychol.* **10**, 2016 (2019).
132. Dimidjian, S., Barrera, M., Martell, C., Muñoz, R. F. & Lewinsohn, P. M. The origins and current status of behavioral activation treatments for depression. *Annu. Rev. Clin. Psychol.* **7**, 1–38 (2011).
133. Shear, M. K. et al. Optimizing treatment of complicated grief: a randomized clinical trial. *JAMA Psychiatry* **73**, 685–694 (2016).
134. Whooley, M. A., Avins, A. L., Miranda, J. & Browner, W. S. Case-finding instruments for depression. *J. Gen. Intern. Med.* **12**, 439–445 (1997).
135. Bosanquet, K. et al. Diagnostic accuracy of the Whooley questions for the identification of depression: a diagnostic meta-analysis. *BMJ Open* **5**, e008913 (2015).
136. Colquhoun, D. M. et al. Screening, referral and treatment for depression in patients with coronary heart disease. *Med. J. Aust.* **198**, 483–484 (2013).
137. World Health Organization. mhGAP intervention guide for mental, neurological and substance use disorders in non-specialized health settings – version 2 (WHO, 2016).
138. Shepard, N. & Parker, C. Depression in adults: recognition and management. *Clin. Pharm.* https://doi.org/10.1211/cp.2017.20202439 (2017).

139. Kroenke, K., Spitzer, R. L. & Williams, J. B. W. The patient health questionnaire-2. *Med. Care* **41**, 1284–1292 (2003).
140. Manea, L. et al. Identifying depression with the PHQ-2: a diagnostic meta-analysis. *J. Affect. Disord.* **203**, 382–395 (2016).
141. Whooley, M. A. Screening for depression — a tale of two questions. *JAMA Intern. Med.* **176**, 436–438 (2016).
142. Levis, B. et al. Accuracy of the PHQ-2 alone and in combination with the PHQ-9 for screening to detect major depression: systematic review and meta-analysis. *JAMA* **323**, 2290–2300 (2020).
143. Kroenke, K., Spitzer, R. L. & Williams, J. B. W. The PHQ-9. *J. Gen. Intern. Med.* **16**, 606–613 (2001).
144. Gilbody, S., Richards, D., Brealey, S. & Hewitt, C. Screening for depression in medical settings with the patient health questionnaire (PHQ): a diagnostic meta-analysis. *J. Gen. Intern. Med.* **22**, 1596–1602 (2007).
145. Mitchell, A. J., Yadegarfar, M., Gill, J. & Stubbs, B. Case finding and screening clinical utility of the patient health questionnaire (PHQ-9 and PHQ-2) for depression in primary care: a diagnostic meta-analysis of 40 studies. *BJPsych Open* **2**, 127–138 (2016).
146. Archer, J. et al. Collaborative care for depression and anxiety problems. *Cochrane Database Syst. Rev.* **10**, CD006525 (2012).
147. Panagioti, M. et al. Association between chronic physical conditions and the effectiveness of collaborative care for depression: an individual participant data meta-analysis. *JAMA Psychiatry* **73**, 978–989 (2016).
148. Cipriani, A. et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet* **391**, 1357–1366 (2018).
149. Rayner, L. et al. Antidepressants for depression in physically ill people. *Cochrane Database Syst. Rev.* **391**, CD007503 (2010).
150. Ostuzzi, G. et al. Efficacy and acceptability of antidepressants in patients with ischemic heart disease. *Int. Clin. Psychopharmacol.* **34**, 65–75 (2019).
151. Ostuzzi, G., Benda, L., Costa, E. & Barbui, C. Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: systematic review and meta-analysis. *Cancer Treat. Rev.* **41**, 714–724 (2015).
152. Baumeister, H., Hutter, N. & Bengel, J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus: an abridged Cochrane review. *Diabet. Med.* **31**, 773–786 (2014).
153. Price, A. et al. Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials. *J. Neurol. Neurosurg. Psychiatry* **82**, 914–923 (2011).
154. Xu, X. et al. Efficacy and feasibility of antidepressant treatment in patients with post-stroke depression. *Medicine* **95**, e5349 (2016).
155. Bomasang-Layno, E., Fadlon, I., Murray, A. N. & Himelhoch, S. Antidepressive treatments for Parkinson's disease: a systematic review and meta-
156. Fiest, K. M. et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. *Mult. Scler. Relat. Disord.* **5**, 12–26 (2016).
157. Ostuzzi, G., Matcham, F., Dauchy, S., Barbui, C. & Hotopf, M. Antidepressants for the treatment of depression in people with cancer. *Cochrane Database Syst. Rev.* https://doi.org/10.1002/14651858.cd011006.pub3 (2018).
158. Fiest, K. M. et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with rheumatoid Arthritis. *J. Clin. Rheumatol.* **23**, 425–434 (2017).
159. Fiest, K. M. et al. Systematic review of interventions for depression and anxiety in persons with inflammatory bowel disease. *BMC Res. Notes* **9**, 404 (2016).
160. Madhusoodanan, S., Velama, U., Parmar, J., Goia, D. & Brenner, R. A current review of cytochrome P450 interactions of psychotropic drugs. *Ann. Clin. Psychiatry* **26**, 120–138 (2014).
161. Rosenblat, J. D., Lee, Y. & McIntyre, R. S. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis. *J. Affect. Disord.* **241**, 484–491 (2018).
162. Kim, B. Y., Sharafoddini, A., Tran, N., Wen, E. Y. & Lee, J. Consumer mobile apps for potential drug-drug interaction check: systematic review and content analysis using the mobile app rating scale (MARS). *JMIR Mhealth Uhealth* **6**, e74 (2018).
163. Apidi, N. A. et al. Mobile medical applications for dosage recommendation, drug adverse reaction, and drug interaction. *Ther. Innov. Regul. Sci.* **51**, 480–485 (2017).
164. Eshun-Wilson, I. et al. Antidepressants for depression in adults with HIV infection. *Cochrane Database Syst. Rev.* https://doi.org/10.1002/14651858.cd008525.pub3 (2018).
165. Zimmermann-Viehoff, F., Kuehl, L. K., Danker-Hopfe, H., Whooley, M. A. & Otte, C. Antidepressants, autonomic function and mortality in patients with coronary heart disease: data from the heart and soul study. *Psychol. Med.* **44**, 2975–2984 (2014).
166. Taylor, D. Antidepressant drugs and cardiovascular pathology: a clinical overview of

effectiveness and safety. *Acta Psychiatr. Scand.* **118**, 434–442 (2008).
167. Pizzi, C. et al. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. *Am. J. Cardiol.* **107**, 972–979 (2011).
168. Beach, S. R. et al. Meta-analysis of selective serotonin reuptake inhibitor–associated QTc prolongation. *J. Clin. Psychiatry* **75**, e441–e449 (2014).
169. Assimon, M. M., Brookhart, M. A. & Flythe, J. E. Comparative cardiac safety of selective serotonin reuptake inhibitors among individuals receiving maintenance hemodialysis. *J. Am. Soc. Nephrol.* **30**, 611–623 (2019).
170. Bahar, M. A., Kamp, J., Borgsteede, S. D., Hak, E. & Wilffert, B. The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine. *Br. J. Clin. Pharmacol.* **84**, 2704–2715 (2018).
171. Köhler-Forsberg, O. et al. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. *Acta Psychiatri. Scand.* **139**, 404–419 (2019).
172. Bu, D., Griffin, G. & Lichtman, A. H. Mechanisms for the anti-inflammatory effects of statins. *Curr. Opin. Lipidol.* **22**, 165–170 (2011).
173. Abajo, F. J. de & García-Rodríguez, L. A. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy. *Arch. Gen. Psychiatry* **65**, 795–803 (2008).
174. Spina, E., Barbieri, M. A., Cicala, G., Bruno, A. & de Leon, J. Clinically relevant drug interactions between newer antidepressants and oral anticoagulants. *Expert. Opin. Drug. Metab. Toxicol.* **16**, 31–44 (2020).
175. Yoon, J. M., Cho, E.-G., Lee, H.-K. & Park, S. M. Antidepressant use and diabetes mellitus risk: a meta-analysis. *Korean J. Fam. Med.* **34**, 228–240 (2013).
176. Domecq, J. P. et al. Drugs commonly associated with weight change: a systematic review and meta-analysis. *J. Clin. Endocrinol. Metab.* **100**, 363–370 (2015).
177. Roopan, S. & Larsen, E. R. Use of antidepressants in patients with depression and comorbid diabetes mellitus: a systematic review. *Acta Neuropsychiatr.* **29**, 127–139 (2016).
178. Williams, L. J. et al. Selective serotonin reuptake inhibitors (SSRIs) and markers of bone turnover in men. *Calcif. Tissue Int.* **103**, 125–130 (2018).
179. Brännström, J., Lövheim, H., Gustafson, Y. & Nordström, P. Association between antidepressant drug use and hip fracture in older people before and after treatment initiation. *JAMA Psychiatry* **76**, 172–179 (2019).
180. Maguire, M. J., Weston, J., Singh, J. & Marson, A. G. Antidepressants for people with epilepsy and depression. *Cochrane Database Syst. Rev.* https://doi.org/10.1002/14651858.CD010682.pub2 (2014).
181. Monaco, F. & Cicolin, A. Interactions between anticonvulsant and psychoactive drugs. *Epilepsia* **40**, s71–s76 (1999).
182. Ogawa, Y. et al. Antidepressants plus benzodiazepines for adults with major depression. *Cochrane Database Syst. Rev.* **6**, CD001026 (2019).
183. Gasim, M. et al. Adverse psychiatric effects of disease-modifying therapies in multiple sclerosis: a systematic review. *Mult. Scler. Relat. Disord.* **26**, 124–156 (2018).
184. Deutsche Gesellschaft für Neurologie. Idiopathisches Parkinson-Syndrom in *Leitlinien für Diagnostik und Therapie in der Neurologie* (DGN, 2016).
185. Lederberg, M. S. & Holland, J. C. in *Handbook of Psychotherapy in Cancer Care* Ch. 1 (Watson, M. & Kissane, D. W.) 1–14 (John Wiley & Sons, Ltd, 2011).
186. Faller, H. et al. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. *J. Clin. Oncol.* **31**, 782–793 (2013).
187. Okuyama, T., Akechi, T., Mackenzie, L. & Furukawa, T. A. Psychotherapy for depression among advanced, incurable cancer patients: a systematic review and meta-analysis. *Cancer Treat. Rev.* **56**, 16–27 (2017).
188. Bortolato, B. et al. Depression in cancer: The many biobehavioral pathways driving tumor progression. *Cancer Treat. Rev.* **52**, 58–70 (2017).
189. Lutgendorf, S. K. & Andersen, B. L. Biobehavioral approaches to cancer progression and survival: mechanisms and interventions. *Am. Psychologist* **70**, 186–197 (2015).
190. Hartung, T. J. et al. The hospital anxiety and depression scale (HADS) and the 9-item patient health questionnaire (PHQ-9) as screening instruments for depression in patients with cancer: depression screening in oncology. *Cancer* **123**, 4236–4243 (2017).
191. Wang, S.-B. et al. Cognitive behavioral therapy for post-stroke depression: a meta-analysis. *J. Affect. Disord.* **235**, 589–596 (2018).
192. Hackett, M. L., Anderson, C. S., House, A. & Xia, J. Interventions for treating depression after stroke. *Cochrane Database Syst. Rev.* https://doi.org/10.1002/14651858.cd003437.pub3 (2008).

193. Ghielen, I. et al. The effects of cognitive behavioral and mindfulness-based therapies on psychological distress in patients with multiple sclerosis, Parkinson's disease and Huntington's disease: two meta-analyses. *J. Psychosom. Res.* **122**, 43–51 (2019).
194. Hind, D. et al. Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis. *BMC Psychiatry* **14**, 5 (2014).
195. Reavell, J., Hopkinson, M., Clarkesmith, D. & Lane, D. A. Effectiveness of cognitive behavioral therapy for depression and anxiety in patients with cardiovascular disease. *Psychosom. Med.* **80**, 742–753 (2018).
196. Li, C. et al. A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for patients with diabetes and depression. *J. Psychosom. Res.* **95**, 44–54 (2017).
197. Chew, B. H., Vos, R. C., Metzendorf, M.-I., Scholten, R. J. & Rutten, G. E. Psychological interventions for diabetes-related distress in adults with type 2 diabetes mellitus. *Cochrane Database Syst. Rev.* **9**, CD011469 (2017).
198. Graham, C. D., Gouick, J., Krahé, C. & Gillanders, D. A systematic review of the use of acceptance and commitment therapy (ACT) in chronic disease and long-term conditions. *Clin. Psychol. Rev.* **46**, 46–58 (2016).
199. Gold, S. M. et al. Control conditions for randomised trials of behavioural interventions in psychiatry: a decision framework. *Lancet Psychiatry* **4**, 725–732 (2017).
200. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. *Lancet* **361**, 799–808 (2003).
201. Meyer, J. P., Swetter, S. K. & Kellner, C. H. Electroconvulsive therapy in geriatric psychiatry: a selective review. *Psychiatr. Clin. North. Am.* **41**, 79–93 (2018).
202. van Diermen, L. et al. Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis. *Br. J. Psychiatry* **212**, 71–80 (2018).
203. Semkovska, M. & McLoughlin, D. M. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. *Biol. Psychiatry* **68**, 568–577 (2010).
204. Mutz, J. et al. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. *BMJ* **364**, l1079 (2019).